Research and experimental development on natural sciences and engineering
FARMAKON AS
Revenue 2025
NOK 1.8m
Operating profit
NOK 287,000
Equity
NOK 571,000
Incorporated
2022
Share capital
NOK 30,000
Key figures · 2025
Current ratio
2.24
Equity ratio
54.4%
Key figures over time · 2025
| Key figures | 2025 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | 15.6% | |
| Net margin (%%) | 11.9% | |
| Return on assets (%%) | 27.3% | |
| Likviditet | ||
| Current ratio | 2.24 | |
| Working capital | 562k | |
| Soliditet | ||
| Equity ratio (%%) | 54.4% | |
| Debt-to-equity ratio | 0.84 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.